{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-003302","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2024-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.458879+00:00","generated_at":"2026-06-01T06:14:24.277360+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arbutus Phase 2a: imdusiran+IFN yields sustained undetectable HBsAg in 33% at 24 weeks","bullets":["33.3% (4/12) on 48wk imdusiran + 24wk IFN had undetectable HBsAg at EOT, sustained 24wk post-treatment.","All six patients with sustained HBsAg loss seroconverted with high anti-HBsAg antibodies (43.8 to >1,000 mIU/mL).","Two of six patients stopped all therapy and maintain undetectable HBsAg and HBV DNA at 12 weeks off therapy.","No SAEs related to imdusiran or IFN; most common TEAEs were transient ALT elevations and injection site bruising."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-003302","json":"https://secwatch.observer/filing/0001171843-24-003302.json","markdown":"https://secwatch.observer/filing/0001171843-24-003302.md","text":"https://secwatch.observer/filing/0001171843-24-003302.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000117184324003302/0001171843-24-003302-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000117184324003302/f8k_060424.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:14:24.277360+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}